NASDAQ$OTLK

Outlook Therapeutics Inc · Q1 2014 earnings

Q1 2014 earnings · · Investor relations

Headline financials

Total Revenue

$2.93M

No prior period
EPS (adj)

-$52.23

No prior period
Net Income

-$4.91M

No prior period
Operating Income

-$4.14M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$5.84M

No prior period

Revenue & EPS history

Outlook Therapeutics · Revenue · Quarterly

$2.93M

Q1 2014
Beat estimate in 4 of 7 quarters(57%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

+5.1%

Avg return

Earnings day

+6.9%

Avg return

5 days after

-0.7%

Avg return

30 days after

61%

25 / 41 earnings

Positive

+48.5%

Q2 2019

Best reaction

-14.6%

Q3 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+1.3%-0.9%
Q1 2026-13.9%-15.7%-31.4%
Q4 2025-2.9%-11.6%-73.6%
Q3 2025+14.1%+23.5%-51.2%
Q2 2025+1.2%+9.9%-0.6%
Q1 2025+1.6%-7.9%-14.7%
Q4 2024+9.4%+11.2%+17.1%
Q3 2024-0.9%-7.6%-16.5%
Q2 2024-0.9%+7.4%+3.6%
Q1 2024+21.2%+13.0%+3.0%
Q4 2023+4.2%+8.2%-18.5%
Q3 2023-3.1%-16.9%-85.3%
Q2 2023+3.5%+16.5%+46.1%
Q1 2023-3.3%-7.5%-15.8%
Q4 2022+6.9%+4.0%+15.8%
Q3 2022-3.4%+5.9%-4.2%
Q2 2022+7.4%+2.7%-37.1%
Q1 2022+3.7%+8.1%+36.3%
Q4 2021-4.2%-1.4%-14.6%
Q3 2021-14.6%-16.2%-1.6%
Q2 2021+16.0%+21.2%+34.1%
Q1 2021-0.4%-4.0%-9.5%
Q4 2020+1.3%-4.6%-13.1%
Q3 2020+5.2%+14.2%-54.5%
Q2 2020+1.9%-1.9%+40.4%
Q1 2020+0.0%-1.1%-35.1%
Q4 2019-1.7%-53.0%-11.1%
Q3 2019-4.2%-8.9%-17.8%
Q2 2019+48.5%+191.3%+125.2%
Q1 2019+28.2%+28.2%-5.8%
Q4 2018+24.5%+42.9%+34.7%
Q3 2018+1.2%-8.8%+0.0%
Q2 2018+2.7%+1.1%-13.3%
Q1 2018+4.3%+3.5%-19.0%
Q4 2017+0.0%-7.9%-4.8%
Q3 2017+0.5%+3.0%+77.8%
Q2 2017-8.7%-34.1%-24.5%
Q1 2017+10.6%+2.1%-1.2%
Q4 2016+28.6%+40.3%+59.8%
Q2 2016+28.6%+40.3%+59.8%
Q3 2016-3.9%-5.3%-8.1%
Q1 2016
Q4 2015
Q3 2015
Q2 2015
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro